Immune-Tag Conjugates™ to go beyond ADCs.
Most solid tumors escape the immune system because they don't look foreign.
Checkpoint inhibitors, ADCs, and CAR-Ts cap at 25–50% response because they ride a single tumor marker, and 40–50% of tumors drop the marker under treatment.
Twenty years of progress taught the immune system to attack. No one taught it where to aim.
We're changing that.
A modular recombinant protein therapy that labels the target cell as if it were infected.
Every adult already carries decades of pathogen-primed T-cell memory against infections they've encountered. ITCs™ redirect it, labeling a target cell as if it were infected, so the body does what it was already trained to do.
Selective. Localized. Non-immunosuppressive.
The IMYUN ITC Trojan Horse Platform is a three-component modular therapy that exploits and redirects vaccine-induced and natural memory immunity.
Modular scaffold docks the tumor surface marker (e.g., HER2).
Delivers a pathogen-derived novel tag inside the tumor cell, creating an illusion that the tumor is infected.
Pre-existing pathogen-primed T-cells recognize and destroy the tagged cells.
Our lead program, ORION™, is in advanced preclinical development for HER2+ bladder cancer (TCC) and head-and-neck squamous cell carcinoma (HNSCC). Technology and in vivo proof of concept have been completed and backed by robust IP.
In a HER2+ BCG-primed model, our lead program ORION™ delivered:
IMYUN brings together seasoned biotech executives, the inventor of the ITC™ platform who built the signal peptide (SP) tag system, and the discoverer of the p21 tumor suppressor who directs the Legorreta Cancer Center at Brown University.
Together, we are working to redefine what is possible in solid tumor immunotherapy.
Get updates from the frontlines of immune redirection.